cause mortality and BSI-related attributable mortality rate was highest for gram-negative bacterial BSI patients (20.3%).
The clinical outcome data of the present study assume significance in view of the high prevalence of multidrug-resistant (MDR) gram-negative bacterial infections in this setting. 2, 3 We have previously reported cases from our center of colistinresistant Klebsiella among both pediatric and adult patients. 4, 5 In the period between 2014 and 2015, we reported 30-day all-cause mortality among patients with carbapenem-resistant E. coli (0%), Klebsiella pneumoniae (40%), P. aeruginosa (50%), and Acinetobacter baumannii (60%). 6 In the current study, the average cost for hospital stay was highest for patients with Candida BSIs (US$12,232 [Rs. 795,134]), followed by those with gram-negative bacterial BSIs (US $4,945 [Rs. 321, 433] ). The average cost for hospital stay was lowest for those with gram-positive bacterial BSIs (US$4,163 [Rs. 270, 607] ). In our previous study, among all cancer patients (and not restricted to those with BSIs), we found that the overall mean LOS was 5.9 days, the average cost of care per admission was US $1,413 (Rs. 95, 208) , and the all-cause mortality rate was 5.7%. 1 The comparison of healthcare outcome measures helps us to understand the efficacy of various clinical interventions, such as chemotherapy regimens and infection prevention and control measures, as well as the effect of infrastructure development or resource allocation. Data on these measures are far less commonly available from low-or middle-income countries than from developed economies, but they are important globally because of the migration of people for work, exigencies or medical tourism. A study from the United States showed that for patients with neutropenia plus infection, the mean hospitalization costs were $27,587, the LOS was 12.6 days, and the mortality rate was 19.4%. 7 In a study from Mexico, the mean cost per hospital stay was US$2,246 among patients with ALL. 8 An Indian study on patients undergoing cardiothoracic surgery, patients with hospital-acquired bacteremia experienced a significantly longer total hospital stay (mean, 22.9 days), longer ICU stay (mean, 11.3 days), a higher mortality rate (mean, 54%), and higher cost (mean, US$14,818) than similar patients without bacteremia. 9 Healthcare service providers must take appropriate measures to mitigate the negative effect of infections on clinical and health economic outcome measures. One of the key interventions to achieve a positive change is an awareness, education, and training program for care providers regarding matters related to infection epidemiology, diagnosis, and appropriate management. An Indian study from a tertiary-care teaching hospital reported that for every dollar spent on training, the return of investment was $236 in avoidance of healthcare-associated infections (HAIs). The infection prevention and control measures introduced in our hospital to mitigate the problem of infection in patients with acute leukemia have included numerous interventions: (1) surveillance culture for detection of MDR bacteria in stool samples and throat swabs, (2) use of direct susceptibility tests on positive blood cultures for early detection of resistant organisms, (3) use of polymerase chain reaction-based rapid detection of carbapenemresistant genes, (4) early empirical therapy with polymyxin based treatment regimens in those previously infected or colonized with carbapenem-resistant multidrug-resistant gram-negative bacteria (MDR-GNB), and (5) accreditation of our infection control systems (NABH Safe I: National Accreditation Board for Hospitals and Healthcare providers). Cost of health care, length of hospital stay, and deaths from infections are affected by many factors, such as human resources, technology, clinical care strategies, which we wish to explore in future controlled studies.
